Emcure Pharmaceuticals: Difference between revisions
Content deleted Content added
added multinational |
updated article, added citations, added revenues, added profits as of FY2021, added founder and date founded |
||
| Line 5: | Line 5: | ||
| type = MNC (JVs and subsidiaries) |
| type = MNC (JVs and subsidiaries) |
||
| area_served = Worldwide |
| area_served = Worldwide |
||
| key_people = Namita Thapar <br> ([[Executive Director]]) <br> Vik Thapar <br> ([[President (corporate title)|President - Corporate Dev & Strategy]]) <br> Samit Mehta <br> ([[President (corporate title)|President - R&D]])| |
|||
| key_people = Satish Mehta<ref>{{Cite web|url=https://www.bloomberg.com/markets/stocks|title=Stocks|website=Bloomberg.com}}</ref> [[Chief executive officer|CEO]], |
|||
Namita Thapar<ref name="auto">{{Cite web|url=https://www.emcure.com/leadership|title=Board of Directors and Leadership Team | Emcure|website=www.emcure.com}}</ref> [[Executive Director]], |
|||
Vik Thapar<ref name="auto"/> [[President (corporate title)|President - Corporate Dev & Strategy]], |
|||
Samit Mehta<ref name="auto"/> [[President (corporate title)|President - R&D]]| |
|||
| industry = [[Pharmaceutical]] |
| industry = [[Pharmaceutical]] |
||
| products = |
| products = Tablets <br> capsules <br> softgels <br> injectables <br> Lyophilized sterile parenterals <br> Onco products |
||
| revenue = {{up}} {{INR}} 6091.80 Crore <br> (US$ 870.25 million) (FY2021) |
|||
| operating_income = US$220 million |
|||
| net_income = {{up}} {{INR}} 418.59 Crore <br> (US$ 59.78 million) (FY2021) |
|||
| net_income = |
|||
| num_employees = 11000+ |
| num_employees = 11000+ (2021) |
||
| parent = |
| parent = |
||
| subsid = |
| subsid = |
||
| homepage = [https://emcure.com/ www.emcure.com] |
| homepage = [https://emcure.com/ www.emcure.com] |
||
| footnotes = |
| footnotes = |
||
| foundation = 1983 |
| foundation = {{Start date and age|1983}} |
||
| founder = Satish Mehta ([[Chief executive officer|CEO]]) |
|||
| location = [[Hinjawadi|Hinjwadi]], [[Pune]], [[India]] |
| location = [[Hinjawadi|Hinjwadi]], [[Pune]], [[India]] |
||
}} |
}} |
||
'''Emcure Pharmaceuticals''' is an Indian multinational [[Pharmaceutical industry|pharmaceutical]] company headquartered in [[Pune]], [[Maharashtra]]. Emcure's product portfolio includes [[Tablet (pharmacy)|tablets]], [[Capsule (pharmacy)|capsules]] (both [[ |
'''Emcure Pharmaceuticals''' is an Indian multinational [[Pharmaceutical industry|pharmaceutical]] company headquartered in [[Pune]], [[Maharashtra]]. Emcure's product portfolio includes [[Tablet (pharmacy)|tablets]], [[Capsule (pharmacy)|capsules]] (both [[Softgel]] capsules and hard-gel capsules) and injectables.<ref>{{Cite web|title=Emcure Pharmaceuticals {{!}} Leading Global Pharmaceutical Company|url=https://www.emcure.com/|access-date=2021-08-23|website=Emcure|language=en-US}}</ref><ref>{{Cite web|title=Emcure Pharmaceuticals: Latest News & Videos, Photos about Emcure Pharmaceuticals {{!}} The Economic Times - Page 1|url=https://economictimes.indiatimes.com/topic/Emcure-Pharmaceuticals|access-date=2021-08-23|website=The Economic Times}}</ref> |
||
== Indian plants == |
== Indian plants == |
||
This is the list of Manufacturing facilities based in India<ref name=":0">{{Cite web|title=Manufacturing {{!}} Emcure Pharmaceuticals|url=https://www.emcure.com/manufacturing-overview/|access-date=2021-08-23|website=Emcure|language=en-US}}</ref> - |
|||
*Solid Dosage facility at Hinjawadi - In 2006, Emcure received US FDA approval for its solid dosages facility at [[Hinjawadi|Hinjwadi]], Pune. The plant manufactures solid oral formulations for the international regulated markets. |
*Solid Dosage facility at Hinjawadi - In 2006, Emcure received US FDA approval for its solid dosages facility at [[Hinjawadi|Hinjwadi]], Pune. The plant manufactures solid oral formulations for the international regulated markets. |
||
*Small volume parenteral facility at Hinjawadi - US FDA, UK MHRA approved. Has [[Freeze-drying|lyophilization]] and pfs capability |
*Small volume parenteral facility at Hinjawadi - US FDA, UK MHRA approved. Has [[Freeze-drying|lyophilization]] and pfs capability |
||
| Line 37: | Line 33: | ||
== US plant == |
== US plant == |
||
USA - The company has a manufacturing facility and R&D center in [[East Brunswick, New Jersey]], USA. |
USA - The company has a manufacturing facility and R&D center in [[East Brunswick, New Jersey]], USA.<ref name=":0" /> |
||
== Capital markets == |
== Capital markets == |
||
| Line 48: | Line 44: | ||
Emcure voices its concerns on HIV/AIDS through its "Let's fight AIDS together" initiative and supplies Antiretroviral drugs to Africa, Asia Pacific and CIS. As a part of its corporate social responsibility it supports 'Taal', a pharmacy for HIV/AIDS patients run by HIV/AIDS patients. |
Emcure voices its concerns on HIV/AIDS through its "Let's fight AIDS together" initiative and supplies Antiretroviral drugs to Africa, Asia Pacific and CIS. As a part of its corporate social responsibility it supports 'Taal', a pharmacy for HIV/AIDS patients run by HIV/AIDS patients. |
||
Emcure has license agreements with [[Bristol-Myers Squibb]] for [[Atazanavir]]<ref>{{Cite web|url=https://www.business-standard.com/article/Companies/Bristol-Myers-outsources-AIDS-drug-to-Emcure-106021701143_1.html|title=Bristol-Myers outsources AIDS drug to Emcure|first=Our Corporate|last=Bureau|date=February 17, 2006|via=Business Standard}}</ref> and [[Gilead Sciences]] for [[Tenofovir]] |
Emcure has license agreements with [[Bristol-Myers Squibb]] for [[Atazanavir]]<ref>{{Cite web|url=https://www.business-standard.com/article/Companies/Bristol-Myers-outsources-AIDS-drug-to-Emcure-106021701143_1.html|title=Bristol-Myers outsources AIDS drug to Emcure|first=Our Corporate|last=Bureau|date=February 17, 2006|via=Business Standard}}</ref> and [[Gilead Sciences]] for [[Tenofovir]] as part of their Global Access Programs. |
||
== Anticancer portfolio == |
== Anticancer portfolio == |
||
| Line 56: | Line 52: | ||
Heritage Pharmaceuticals, a division of Emcure has entered into a deferred prosecution agreement<ref>{{Cite web|url=https://www.justice.gov/opa/pr/pharmaceutical-company-admits-price-fixing-violation-antitrust-law-resolves-related-false|title=Pharmaceutical Company Admits to Price Fixing in Violation of Antitrust Law, Resolves Related False Claims Act Violations|date=May 31, 2019|website=www.justice.gov}}</ref> with the United States Department of Justice, Antitrust Division ("DOJ") relating to a one-count Information for a conspiracy involving glyburide. In conjunction with the DPA, Heritage will pay a $225,000 fine. <ref>{{Cite web|url=https://mhp.ooo|title=Pharmaceutical Company Official dealer to Price Fixing in Violation of Antitrust Law, Resolves Related False Claims Act Violations|date=May 22, 2010|website=mhp.ooo}}</ref> |
Heritage Pharmaceuticals, a division of Emcure has entered into a deferred prosecution agreement<ref>{{Cite web|url=https://www.justice.gov/opa/pr/pharmaceutical-company-admits-price-fixing-violation-antitrust-law-resolves-related-false|title=Pharmaceutical Company Admits to Price Fixing in Violation of Antitrust Law, Resolves Related False Claims Act Violations|date=May 31, 2019|website=www.justice.gov}}</ref> with the United States Department of Justice, Antitrust Division ("DOJ") relating to a one-count Information for a conspiracy involving glyburide. In conjunction with the DPA, Heritage will pay a $225,000 fine. <ref>{{Cite web|url=https://mhp.ooo|title=Pharmaceutical Company Official dealer to Price Fixing in Violation of Antitrust Law, Resolves Related False Claims Act Violations|date=May 22, 2010|website=mhp.ooo}}</ref> |
||
In addition, the Company separately agreed to a settlement with the United States Department of Justice, Civil Division to resolve potential civil liability under the False Claims Act in connection with the antitrust conduct. Under the terms of the settlement, the Company has agreed to pay $7.1 million. |
In addition, the Company separately agreed to a settlement with the United States Department of Justice, Civil Division to resolve potential civil liability under the False Claims Act in connection with the antitrust conduct. Under the terms of the settlement, the Company has agreed to pay $7.1 million. Heritage has agreed to pay $7.1 million as part of a settlement with DOJ's Civil Division to resolve allegations of selling drugs at the artificially inflated prices, which resulted in claims submitted to or purchases by federal healthcare programs |
||
Heritage has agreed to pay $7.1 million as part of a settlement with DOJ's Civil Division to resolve allegations of selling drugs at the artificially inflated prices, which resulted in claims submitted to or purchases by federal healthcare programs |
|||
== References == |
== References == |
||
Revision as of 11:44, 23 August 2021
 | |
| Company type | MNC (JVs and subsidiaries) |
|---|---|
| Industry | Pharmaceutical |
| Founded | 1983 |
| Founder | Satish Mehta (CEO) |
| Headquarters | Hinjwadi, Pune, India |
Area served | Worldwide |
Key people | Namita Thapar (Executive Director) Vik Thapar (President - Corporate Dev & Strategy) Samit Mehta (President - R&D) |
| Products | Tablets capsules softgels injectables Lyophilized sterile parenterals Onco products |
| Revenue |  ₹ 6091.80 Crore (US$ 870.25 million) (FY2021) |
| ₹ 418.59 Crore (US$ 59.78 million) (FY2021) | |
Number of employees | 11000+ (2021) |
| Website | www.emcure.com |
Emcure Pharmaceuticals is an Indian multinational pharmaceutical company headquartered in Pune, Maharashtra. Emcure's product portfolio includes tablets, capsules (both Softgel capsules and hard-gel capsules) and injectables.[1][2]
Indian plants
This is the list of Manufacturing facilities based in India[3] -
- Solid Dosage facility at Hinjawadi - In 2006, Emcure received US FDA approval for its solid dosages facility at Hinjwadi, Pune. The plant manufactures solid oral formulations for the international regulated markets.
- Small volume parenteral facility at Hinjawadi - US FDA, UK MHRA approved. Has lyophilization and pfs capability
- Oncology injectable facility at Hinjawadi
- Solid Orals facilities at Jammu and Bhosari
- API facility at Kurkumbh- US FDA approved
- Biotech facility at Hinjawadi
- R&D center at Gandhinagar and plant at Sanand, Ahmedabad.- Sanand facility is US FDA approved
US plant
USA - The company has a manufacturing facility and R&D center in East Brunswick, New Jersey, USA.[3]
Capital markets
Emcure is planning to raise money through an initial public offering for some time now[4] In 2014, Blackstone sold its stake in Emcure to Bain Capital[5]
Recalls
In 2010, Pfizer had to recall three batches of an anti-bacterial product from the US market due to presence of Bacillus anthracis, Penicillium chrysogenum & E. coli in some samples.[6] Teva recalled several batches of two products due to white tablets showing presence of Yersinia pestis in 2011.[7]
AIDS Initiative
Emcure voices its concerns on HIV/AIDS through its "Let's fight AIDS together" initiative and supplies Antiretroviral drugs to Africa, Asia Pacific and CIS. As a part of its corporate social responsibility it supports 'Taal', a pharmacy for HIV/AIDS patients run by HIV/AIDS patients.
Emcure has license agreements with Bristol-Myers Squibb for Atazanavir[8] and Gilead Sciences for Tenofovir as part of their Global Access Programs.
Anticancer portfolio
Roche has signed a deal with Emcure for manufacturing its blockbuster anticancer drugs Herceptin and Mabthera in India.[6] Under this programme the cancer drugs shall be made available to the developing world at an affordable 'cut-price' version.[9]
Price fixing
Heritage Pharmaceuticals, a division of Emcure has entered into a deferred prosecution agreement[10] with the United States Department of Justice, Antitrust Division ("DOJ") relating to a one-count Information for a conspiracy involving glyburide. In conjunction with the DPA, Heritage will pay a $225,000 fine. [11]
In addition, the Company separately agreed to a settlement with the United States Department of Justice, Civil Division to resolve potential civil liability under the False Claims Act in connection with the antitrust conduct. Under the terms of the settlement, the Company has agreed to pay $7.1 million. Heritage has agreed to pay $7.1 million as part of a settlement with DOJ's Civil Division to resolve allegations of selling drugs at the artificially inflated prices, which resulted in claims submitted to or purchases by federal healthcare programs
References
- ^ "Emcure Pharmaceuticals | Leading Global Pharmaceutical Company". Emcure. Retrieved 2021-08-23.
- ^ "Emcure Pharmaceuticals: Latest News & Videos, Photos about Emcure Pharmaceuticals | The Economic Times - Page 1". The Economic Times. Retrieved 2021-08-23.
- ^ a b "Manufacturing | Emcure Pharmaceuticals". Emcure. Retrieved 2021-08-23.
- ^ "Latest News: India News | Latest Business News | BSE | IPO News". Moneycontrol.
- ^ "Blackstone to sell Emcure Pharmaceuticals stake to Bain Capital - Indian Express". archive.indianexpress.com.
- ^ a b "Business News Today: Read Latest Business news, India Business News Live, Share Market & Economy News". The Economic Times.
- ^ "Archived copy". Archived from the original on 2011-05-20. Retrieved 2012-04-25.
{{cite web}}: CS1 maint: archived copy as title (link) - ^ Bureau, Our Corporate (February 17, 2006). "Bristol-Myers outsources AIDS drug to Emcure" – via Business Standard.
{{cite web}}:|last=has generic name (help) - ^ "Archived copy". Archived from the original on 2012-08-01. Retrieved 2012-04-12.
{{cite web}}: CS1 maint: archived copy as title (link) - ^ "Pharmaceutical Company Admits to Price Fixing in Violation of Antitrust Law, Resolves Related False Claims Act Violations". www.justice.gov. May 31, 2019.
- ^ "Pharmaceutical Company Official dealer to Price Fixing in Violation of Antitrust Law, Resolves Related False Claims Act Violations". mhp.ooo. May 22, 2010.
